ARTV vs. VIR, AVXL, PSTX, ADPT, REPL, LENZ, IMTX, RLAY, CGEM, and TECX
Should you be buying Artiva Biotherapeutics stock or one of its competitors? The main competitors of Artiva Biotherapeutics include Vir Biotechnology (VIR), Anavex Life Sciences (AVXL), Poseida Therapeutics (PSTX), Adaptive Biotechnologies (ADPT), Replimune Group (REPL), LENZ Therapeutics (LENZ), Immatics (IMTX), Relay Therapeutics (RLAY), Cullinan Therapeutics (CGEM), and Tectonic Therapeutic (TECX). These companies are all part of the "biological products, except diagnostic" industry.
Artiva Biotherapeutics vs.
Vir Biotechnology (NASDAQ:VIR) and Artiva Biotherapeutics (NASDAQ:ARTV) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, media sentiment, analyst recommendations, profitability, risk, community ranking, dividends and earnings.
Artiva Biotherapeutics has a net margin of 0.00% compared to Vir Biotechnology's net margin of -678.40%. Artiva Biotherapeutics' return on equity of 0.00% beat Vir Biotechnology's return on equity.
65.3% of Vir Biotechnology shares are owned by institutional investors. 15.6% of Vir Biotechnology shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
In the previous week, Artiva Biotherapeutics had 13 more articles in the media than Vir Biotechnology. MarketBeat recorded 14 mentions for Artiva Biotherapeutics and 1 mentions for Vir Biotechnology. Artiva Biotherapeutics' average media sentiment score of 1.16 beat Vir Biotechnology's score of -0.44 indicating that Artiva Biotherapeutics is being referred to more favorably in the news media.
Artiva Biotherapeutics has lower revenue, but higher earnings than Vir Biotechnology.
Vir Biotechnology currently has a consensus price target of $36.40, suggesting a potential upside of 385.33%. Artiva Biotherapeutics has a consensus price target of $21.00, suggesting a potential upside of 96.81%. Given Vir Biotechnology's higher possible upside, equities analysts clearly believe Vir Biotechnology is more favorable than Artiva Biotherapeutics.
Vir Biotechnology received 40 more outperform votes than Artiva Biotherapeutics when rated by MarketBeat users. However, 100.00% of users gave Artiva Biotherapeutics an outperform vote while only 53.26% of users gave Vir Biotechnology an outperform vote.
Summary
Artiva Biotherapeutics beats Vir Biotechnology on 9 of the 14 factors compared between the two stocks.
Get Artiva Biotherapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ARTV and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Artiva Biotherapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:ARTV) was last updated on 1/6/2025 by MarketBeat.com Staff
